The DOI matches its Crossref record; 255 of the 256 references it cites were found in a registry or an index.
mRNA-based therapeutics--developing a new class of drugs
Open accessAbstract
In vitro transcribed (IVT) mRNA has recently come into focus as a potential new drug class to deliver genetic information. Such synthetic mRNA can be engineered to transiently express proteins by structurally resembling natural mRNA. Advances in addressing the inherent challenges of this drug class, particularly related to controlling the translational efficacy and immunogenicity of the IVTmRNA, provide the basis for a broad range of potential applications. mRNA-based cancer immunotherapies and infectious disease vaccines have entered clinical development. Meanwhile, emerging novel approaches include in vivo delivery of IVT mRNA to replace or supplement proteins, IVT mRNA-based generation of pluripotent stem cells and genome engineering using IVT mRNA-encoded designer nucleases. This Review provides a comprehensive overview of the current state of mRNA-based drug technologies and their applications, and discusses the key challenges and opportunities in developing these into a new class of drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mRNA vaccines still suffer from decreased efficacy due to poor RNA stability in solution and in vivo and to limited expression of the payload mRNA; these are all pivotal issues that need to be carefully optimized for preclinical and clinical applications3–6.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, we focused on ψ and m1ψ, since these substitutions for U have been widely adopted for mRNA therapeutics and vaccines due to improved in-cell translation and to better control of innate immune responses2,3,8,67 through avoidance of recognition by cellular toll-like receptors (TLR7 and TLR8)68, RIG‑I, and PKR69–71.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IVT is a low-cost method of mRNA synthesis; however the immunogenicity of mRNA is the most challenging obstacle it faces (Sahin et al. 2014).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The 3ʹ-UTRs of α- and β-globin mRNAs are found in many in vitro-transcribed (IVT) mRNA, and they contain sequence features that enhance the translation and stability of mRNA (Sahin et al. 2014; Karikó et al. 1999).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“The 7-methylguanosine (m7G) moiety is found at the 5′ end of natural mRNA in the eukaryotic cytoplasm, followed by a triphosphate connection to the first nucleotide (m7GpppN) (Sahin et al. 2014).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“The basic structure of mRNA, same as eukaryotic mRNA, is made up of (i) protein encoding ORF, surrounded by (ii) 5′ and 3′ UTRs, and (iii) a 7-methyl guanosine 5′ cap structure and (iv) a 3′poly(A) tail at the end sides (Verbeke et al. 2019; Schlake et al. 2012; Sahin et al. 2014) (Fig. 1).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“The 3ʹ-UTRs of α- and β-globin mRNAs are found in many in vitro-transcribed (IVT) mRNA, and they contain sequence features that enhance the translation and stability of mRNA (Sahin et al. 2014; Karikó et al. 1999).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“IVT is a low-cost method of mRNA synthesis; however the immunogenicity of mRNA is the most challenging obstacle it faces (Sahin et al. 2014).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Sahin et al. 2014
In the citing paper
“Since the 3′-OH group in proximity to m7G is methylated, thus the ARCA cap analog can only bind the 5′ end of mRNA in forward orientation, which is recognized by the eukaryotic translation initiation factor 4E (eIF4E) to initiate ribosome recruitment and translation.74,125”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [74]
In the citing paper
“The host immune system can easily recognize unmodified mRNA or by-products formed during IVT of engineered mRNA as exogenous molecules.74”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [74]
In the citing paper
“Tfh cells recognize antigens on the APC surface and help to activate B cells, which in turn produce high-affinity virus-neutralizing antibodies.6,55, 56, 57”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [57]
In the citing paper
“Tfh cells further help activate CD8+ cytotoxic T cells that may specifically recognize and eliminate virus-infected cells (Figure 1).6,55, 56, 57”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [57]
In the citing paper
“mRNA has shown therapeutic potential in a range of applications, including viral vaccines, protein replacement therapies, cancer immunotherapies, cellular reprogramming and genome editing2,4,7–17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“These elements can be engineered to improve the stability and translational efficiency of mRNA2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“mRNA is susceptible to degradation and, thus, formulation buffers should be free of any ribonuclease contaminations2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“mRNA normally contains five structural elements, that is, a 5′ cap, a 3′ poly(A) tail, a protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Chromatographic purification can remove double-stranded RNA, an analogue of viral genome, in IVT mRNA preparations, diminishing immune activation and increasing translational efficiency2,4,7,183.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Many other lipid nanoparticle–mRNA formulations are in clinical trials for the treatment of infectious diseases, cancer and genetic disorders2,4,8,12–14 (Tables 1,2).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Chemical modifications of specific IVT mRNA nucleotides, such as pseudouridine (ψ) and N1-methylpseudouridine (m1ψ), can reduce innate immune sensing of exogenous mRNA translation2,4,7,182.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“To address these concerns, the engineering of mRNA molecules (Box 1) and the design of lipid nanoparticles have been optimized2,4,7–17, which has contributed to the rapid development and clinical assessment15,17 of the two COVID-19 mRNA vaccines, mRNA-1273 (NCT04470427)19,20 and BNT162b2 (NCT04368728)21.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Finally, GMP-grade lipid nanoparticle-mRNA vaccines can be manufactured for specific antigens in a short period of time, compared with other vaccine platforms, such as recombinant proteins and inactivated vaccines2,4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Moreover, mRNA-based cellular reprogramming, tissue regeneration and genome editing have shown therapeutic potential in preclinical studies2,4,8,12–14.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Compared with regular mRNA, self-amplifying RNA (also termed replicon), which was originally derived from an alphavirus genome, has similar basic elements (5′ cap, 5′ and 3′ untranslated regions, 3′ poly(A) tail) and a long coding region.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“After delivery into the cytoplasm, self-amplifying RNA (positive-strand mRNA) functions as a translation template for the production of the RDRP.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“The coding region contains the sequences for an RNA-dependent RNA polymerase (RDRP), a promoter and structural viral proteins (also known as subgenomic sequence).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Meanwhile, the promoter in the negative-strand RNA is recognized by the RDRP, leading to the transcription of capped subgenomic RNA that encodes structural viral proteins.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“This self-amplification process allows the mass production of virions from limited amounts of virus at infection.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Replacing the subgenomic sequence by a gene of interest enables high-level expression of desired proteins.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“The initial replication leads to negative-strand RNA, which acts as template for the generation of the positive-strand viral genome.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“The transient replication generates double-stranded RNA (dsRNA) and, thus, self-amplifying RNA tends to activate innate immune pathways.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“Moreover, the positive-strand mRNA serves as a genomic template for RDRP-mediated replication.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“To achieve effective translation, mRNA requires five structural elements, including the 5′ cap, 3′ poly(A) tail, protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“The sequences of these elements regulate translation initiation, translation termination and post-transcriptional modification of mRNA molecules2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [2]
In the citing paper
“mRNA functions as the bridge between DNA and proteins in eukaryotic cells.[8, 12, 119]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [119]
In the citing paper
“Compared with protein drugs, mRNA can supplement both cytoplasmic and large transmembranic proteins.[8, 119, 120]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [119]
In the citing paper
“Relative to plasmid DNA (pDNA), mRNA possesses temporary bioactivity and functions outside the nucleus, leading to a more controllable protein expression and avoiding the potential insertion of the genome.[8, 119, 120]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [119]
In the citing paper
“Protein-encoding mRNA has emerged as an attractive new technology for gene delivery.1”
From Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening (2019) · cites this paper as [1]
In the citing paper
“Robust induction of an immune response by a cancer vaccine requires efficient expression of the vaccine antigen-encoding mRNA specifically in DCs to achieve a high density of epitope-loaded MHCs.1,42”
From Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening (2019) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., & Fujita, T. (2004) · Nature Immunology · doi:10.1038/ni1087 · Cited by 4,022
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Flagged first, then by citations
1 of the 256 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Prieels, J.-P. et al. Mastering industrialization of cell therapy products. BioProcess Int. 10, S12–S15 (2012).
Cited by
Sorted by citations
Items 101–200 of 1,005
Svitkin, Y. V., Cheng, Y. M., Chakraborty, T., Presnyak, V., John, M., & Sonenberg, N. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx135 · Cited by 278
MacLeod, D. T., Antony, J., Martin, A. J., Moser, R. J., Hekele, A., Wetzel, K. J., Brown, A. E., Triggiano, M. A., Hux, J. A., Pham, C. D., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.005 · Cited by 285
Paunovska, K., Sago, C. D., Monaco, C. M., Hudson, W. H., Castro, M. G., Rudoltz, T. G., Kalathoor, S., Vanover, D. A., Santangelo, P. J., Ahmed, R., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b00432 · Cited by 277
From the RNA world to the clinic
Sullenger, B. A., & Nair, S. (2016) · Science · doi:10.1126/science.aad8709 · Cited by 274
Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis
Robinson, E., MacDonald, K. D., Slaughter, K., McKinney, M., Patel, S., Sun, C., & Sahay, G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.014 · Cited by 272
Principles for designing an optimal mRNA lipid nanoparticle vaccine
Kon, E., Elia, U., & Peer, D. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.09.016 · Cited by 269
Lipid Nanoparticle–mRNA Formulations for Therapeutic Applications
Wang, C., Zhang, Y., & Dong, Y. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00550 · Cited by 276
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia
An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H. A., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 271
An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo
Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261
Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy
You, Y., Tian, Y., Yang, Z., Shi, J., Kwak, K. J., Tong, Y., Estania, A. P., Cao, J., Hsu, W.-H., Liu, Y., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00989-w · Cited by 258
Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy
Guevara, M. L., Persano, F., & Persano, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.589959 · Cited by 261
Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
Kiaie, S. H., Zolbanin, N. M., Ahmadi, A., Bagherifar, R., Valizadeh, H., Kashanchi, F., & Jafari, R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01478-7 · Cited by 269
Kim, S. C., Sekhon, S. S., Shin, W.-R., Ahn, G., Cho, B.-K., Ahn, J.-Y., & Kim, Y.-H. (2022) · Molecular & Cellular Toxicology · doi:10.1007/s13273-021-00171-4 · Cited by 255
Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery
Nogueira, S. S., Schlegel, A., Maxeiner, K., Weber, B., Barz, M., Schroer, M. A., Blanchet, C. E., Svergun, D. I., Ramishetti, S., Peer, D., et al. (2020) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c01834 · Cited by 252
Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery
Fenton, O. S., Kauffman, K. J., McClellan, R. L., Appel, E. A., Dorkin, J. R., Tibbitt, M. W., Heartlein, M. W., DeRosa, F., Langer, R., & Anderson, D. G. (2016) · Advanced Materials · doi:10.1002/adma.201505822 · Cited by 252
Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA
Patel, S., Ashwanikumar, N., Robinson, E., DuRoss, A., Sun, C., Murphy-Benenato, K. E., Mihai, C., Almarsson, Ö., & Sahay, G. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b02664 · Cited by 251
Zhang, H., You, X., Wang, X., Cui, L., Wang, Z., Xu, F., Li, M., Yang, Z., Liu, J., Huang, P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005191118 · Cited by 252
Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9
Zhang, H., Zhang, Y., & Yin, H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.014 · Cited by 256
Han, X., Alameh, M., Butowska, K., Knox, J. J., Lundgreen, K. A., Ghattas, M., Gong, N., Xue, L., Xu, Y., Lavertu, M., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01404-4 · Cited by 255
Li, Y., Ma, X., Yue, Y., Zhang, K., Cheng, K., Feng, Q., Ma, N., Liang, J., Zhang, T., Zhang, L., et al. (2022) · Advanced Materials · doi:10.1002/adma.202109984 · Cited by 247
mRNA vaccines in disease prevention and treatment
Zhang, G., Tang, T., Chen, Y., Huang, X., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01579-1 · Cited by 273
Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
Zhang, L., More, K. R., Ojha, A., Jackson, C. B., Quinlan, B. D., Li, H., He, W., Farzan, M., Pardi, N., & Choe, H. (2023) · npj Vaccines · doi:10.1038/s41541-023-00751-6 · Cited by 244
Progress in material design for biomedical applications
Tibbitt, M. W., Rodell, C. B., Burdick, J. A., & Anseth, K. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516247112 · Cited by 244
McKinlay, C. J., Benner, N. L., Haabeth, O. A. W., Waymouth, R. M., & Wender, P. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805358115 · Cited by 242
Recent trends in cancer therapy: A review on the current state of gene delivery
Yahya, E. B., & Alqadhi, A. M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119087 · Cited by 251
An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts
Dousis, A. D., Ravichandran, K. R., Hobert, E. M., Moore, M. J., & Rabideau, A. E. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01525-6 · Cited by 259
Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines
Aldosari, B. N., Alfagih, I. M., & Almurshedi, A. S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020206 · Cited by 248
Encapsulation state of messenger RNA inside lipid nanoparticles
Brader, M. L., Williams, S. J., Banks, J. M., Hui, W. H., Zhou, Z. H., & Jin, L. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.03.012 · Cited by 236
Mechanism of action of mRNA-based vaccines
Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1355245 · Cited by 234
Parhiz, H., Shuvaev, V. V., Pardi, N., Khoshnejad, M., Kiseleva, R. Y., Brenner, J. S., Uhler, T., Tuyishime, S., Mui, B. L., Tam, Y. K., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.015 · Cited by 233
Cap 1 Messenger RNA Synthesis with Co‐transcriptional CleanCap ® Analog by In Vitro Transcription
Henderson, J. M., Ujita, A., Hill, E., Yousif‐Rosales, S., Smith, C., Ko, N., McReynolds, T., Cabral, C. R., Escamilla‐Powers, J. R., & Houston, M. E. (2021) · Current Protocols · doi:10.1002/cpz1.39 · Cited by 231
John, S., Yuzhakov, O., Woods, A., Deterling, J., Hassett, K., Shaw, C. A., & Ciaramella, G. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.01.029 · Cited by 229
Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery
Wróblewska, L., Kitada, T., Endo, K., Siciliano, V., Stillo, B., Saito, H., & Weiss, R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3301 · Cited by 224
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives
Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez‐Gascón, A., Solinís, M. Á., & del Pozo‐Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 229
Jeong, M., Lee, Y., Park, J., Jung, H., & Lee, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114990 · Cited by 232
Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening
Guimarães, P. P. G., Zhang, R., Spektor, R., Tan, M., Chung, A., Billingsley, M. M., El-Mayta, R. D., Riley, R., Wang, L., Wilson, J. M., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.028 · Cited by 224
Cheng, Q., Wei, T., Jia, Y., Farbiak, L., Zhou, K., Zhang, S., Wei, Y., Zhu, H., & Siegwart, D. J. (2018) · Advanced Materials · doi:10.1002/adma.201805308 · Cited by 221
RNA-Based Vaccines in Cancer Immunotherapy
McNamara, M. A., Nair, S. K., & Holl, E. K. (2015) · Journal of Immunology Research · doi:10.1155/2015/794528 · Cited by 229
Claudin 18.2 as a novel therapeutic target
Nakayama, I., Qi, C., Chen, Y., Nakamura, Y., Shen, L., & Shitara, K. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00874-2 · Cited by 243
mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo
Rybakova, Y., Kowalski, P. S., Huang, Y., Gonzalez, J. T., Heartlein, M. W., DeRosa, F., Delcassian, D., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.012 · Cited by 218
Hotz, C., Wagenaar, T. R., Gieseke, F., Bangari, D. S., Callahan, M., Cao, H., Diekmann, J., Diken, M., Grunwitz, C. R., Hebert, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc7804 · Cited by 223
Self-citationAn origin of the immunogenicity of in vitro transcribed RNA
Mu, X., Greenwald, E., Ahmad, S., & Hur, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky177 · Cited by 218
Chi, W.-Y., Li, Y.-D., Huang, H., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 225
A Deep Neural Network for Predicting and Engineering Alternative Polyadenylation
Bogard, N., Linder, J., Rosenberg, A. B., & Seelig, G. (2019) · Cell · doi:10.1016/j.cell.2019.04.046 · Cited by 215
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Shi, Y., Shi, M., Wáng, Y., & You, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02002-z · Cited by 243
A trans-amplifying RNA vaccine strategy for induction of potent protective immunity
Beissert, T., Perkovic, M., Vogel, A., Erbar, S., Walzer, K. C., Hempel, T., Brill, S., Haefner, E., Becker, R., Türeci, Ö., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.009 · Cited by 212
Self-citationSchnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004746 · Cited by 212
Chugh, V., Krishna, K. V., & Pandit, A. S. (2021) · ACS Nano · doi:10.1021/acsnano.1c03800 · Cited by 219
Cationic surfactants: A review
Gonçalves, R. A., Holmberg, K., & Lindman, B. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.121335 · Cited by 211
Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery
Wang, W., Chen, K., Jiang, T. S., Wu, Y., Wu, Z., Ying, H., Yu, H., Lu, J., Lin, J., & Ouyang, D. (2024) · Nature Communications · doi:10.1038/s41467-024-55072-6 · Cited by 247
The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case
Blenke, E. O., Örnskov, E., Schöneich, C., Nilsson, G. Å., Volkin, D. B., Mastrobattista, E., Almarsson, Ö., & Crommelin, D. J. A. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.11.001 · Cited by 221
Kwon, H., Kim, M., Seo, Y., Moon, Y. S., Lee, H. J., Lee, K., & Lee, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.034 · Cited by 208
Lipid-based mRNA vaccine delivery systems
Midoux, P., & Pichon, C. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.986104 · Cited by 213
Natural polyphenols in drug delivery systems: Current status and future challenges
Wang, H., Wang, C., Zou, Y., Hu, J., Li, Y., & Cheng, Y. (2020) · Giant · doi:10.1016/j.giant.2020.100022 · Cited by 207
Comparison of DNA and mRNA vaccines against cancer
Jahanafrooz, Z., Baradaran, B., Mosafer, J., Hashemzaei, M., Rezaei, T., Mokhtarzadeh, A., & Hamblin, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.003 · Cited by 202
Liu, Q., Li, D., Pan, X., & Liang, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02081-0 · Cited by 201
Biomaterials for vaccine-based cancer immunotherapy
Zhang, R., Billingsley, M. M., & Mitchell, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.008 · Cited by 204
Sedic, M., Senn, J. J., Lynn, A., Laska, M., Smith, M., Platz, S. J., Bolen, J., Hoge, S., Bulychev, A., Jacquinet, E., et al. (2018) · Veterinary Pathology · doi:10.1177/0300985817738095 · Cited by 195
The Human Vaccines Project: A roadmap for cancer vaccine development
Romero, P. J., Banchereau, J., Bhardwaj, N., Cockett, M. I., Disis, M. L., Dranoff, G., Gilboa, E., Hammond, S. A., Hershberg, R. D., Korman, A. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf0685 · Cited by 197
Self-citationKauffman, K. J., Mir, F. F., Jhunjhunwala, S., Kaczmarek, J. C., Hurtado, J. E., Yang, J. H., Webber, M. J., Kowalski, P. S., Heartlein, M. W., DeRosa, F., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.006 · Cited by 195
Coolen, A.-L., Lacroix, C., Mercier‐Gouy, P., Delaune, E. A., Monge, C., Exposito, J., & Verrier, B. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.019 · Cited by 198
Rational designs of in vivo CRISPR-Cas delivery systems
Xu, C., Chen, G., Luo, Y., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.005 · Cited by 187
Xue, L., Gong, N., Shepherd, S. J., Xiong, X., Liao, X., Han, X., Zhao, G., Song, C., Huang, X., Zhang, H., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c02706 · Cited by 191
Polymer‐Based mRNA Delivery Strategies for Advanced Therapies
Yang, W., Mixich, L., Boonstra, E., & Cabral, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202688 · Cited by 201
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs
Rañoa, D. R. E., Parekh, A. D., Pitroda, S. P., Huang, X., Darga, T. E., Wong, A., Huang, L., Andrade, J., Staley, J. P., Satoh, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8420 · Cited by 184
Clinical and immunological effects of mRNA vaccines in malignant diseases
Heine, A., Juranek, S., & Brossart, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01339-1 · Cited by 186
Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines
Swetha, K., Kotla, N. G., Tunki, L., Jayaraj, A., Bhargava, S. K., Hu, H., Bonam, S. R., & Kurapati, R. (2023) · Vaccines · doi:10.3390/vaccines11030658 · Cited by 196
Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing
Zhang, X., Zhao, W., Nguyen, G. N., Zhang, C., Zeng, C., Yan, J., Du, S., Hou, X., Li, W., Jiang, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc2315 · Cited by 184
Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide
Qiu, Y., Man, R. C. H., Liao, Q., Kung, K. L. K., Chow, M. Y. T., & Lam, J. K. W. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.026 · Cited by 178
Meyer, M., Huang, E., Yuzhakov, O., Ramanathan, P., Ciaramella, G., & Bukreyev, A. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix592 · Cited by 178
Whitley, J., Zwolinski, C., Denis, C., Maughan, M., Hayles, L., Clarke, D., Snare, M., Liao, H., Chiou, S., Marmura, T., et al. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.009 · Cited by 188
mRNA vaccines for cancer immunotherapy
Vishweshwaraiah, Y. L., & Dokholyan, N. V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1029069 · Cited by 184
Delivery strategies of cancer immunotherapy: recent advances and future perspectives
Zhao, Z., Zheng, L., Chen, W., Weng, W., Song, J., & Ji, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0817-3 · Cited by 183
Liu, S., Wang, X., Yu, X., Cheng, Q., Johnson, L. T., Chatterjee, S., Zhang, D., Lee, S. M., Sun, Y., Lin, T., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c09822 · Cited by 175
Biomaterials for mRNA delivery
Islam, M. A., Reesor, E. K. G., Xu, Y., Zope, H. R., Zetter, B. R., & Shi, J. (2015) · Biomaterials Science · doi:10.1039/c5bm00198f · Cited by 176
Wang, Y., Kumari, M., Chen, G., Hong, M.-H., Yuan, J. P., Tsai, J.-L., & Wu, H. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00977-5 · Cited by 198
Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery
Herrera‐Barrera, M., Kim, J., Eygeris, Y., Jozić, A., & Sahay, G. (2021) · Biomaterials Science · doi:10.1039/d0bm01947j · Cited by 180
Nanoscale platforms for messenger RNA delivery
Li, B., Zhang, X., & Dong, Y. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1530 · Cited by 170
Nanotechnology Responses to COVID‐19
Ruiz‐Hitzky, E., Darder, M., Wicklein, B., Ruiz‐García, C., Martín‐Sampedro, R., del Real, G., & Aranda, P. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000979 · Cited by 175
Recent Advancement in mRNA Vaccine Development and Applications
Fayez, N. A., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., Alawad, A. O., & Tawfik, E. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071972 · Cited by 187
Nanotechnology-based mRNA vaccines
Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 177
Udhayakumar, V. K., De Beuckelaer, A., McCaffrey, J., McCrudden, C. M., Kirschman, J. L., Vanover, D., Van Hoecke, L., Roose, K., Deswarte, K., De Geest, B. G., et al. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201601412 · Cited by 169
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm
Wang, W., Feng, S., Ye, Z., Gao, H., Lin, J., & Ouyang, D. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.021 · Cited by 173
Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing
Qiu, M., Li, Y., Bloomer, H., & Xu, Q. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00500 · Cited by 168
Zhu, X., Yin, L., Theisen, M., Zhuo, J., Siddiqui, S., Levy, B., Presnyak, V., Frassetto, A., Milton, J., Salerno, T., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.003 · Cited by 165
mRNA cancer vaccines: Advances, trends and challenges
He, Q., Gao, H., Tan, D., Zhang, H., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.011 · Cited by 171
MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct
Jain, R., Frederick, J. P., Huang, E. Y., Burke, K. E., Mauger, D. M., Andrianova, E. A., Farlow, S. J., Siddiqui, S., Pimentel, J., Cheung-Ong, K., et al. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0734 · Cited by 164
Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside
Zatsepin (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s106625 · Cited by 162
Kis, Z., Kontoravdi, C., Shattock, R. J., & Shah, N. (2020) · Vaccines · doi:10.3390/vaccines9010003 · Cited by 164
Chen, Q., Zhang, F., Dong, L., Wu, H., Xu, J., Li, H., Wang, J., Zhou, Z., Liu, C., Wang, Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0389-3 · Cited by 160
Li, F., Zhang, X., Ho, W., Tang, M., Li, Z., Bu, L., & Xu, X. (2023) · Nature Communications · doi:10.1038/s41467-023-39938-9 · Cited by 167
Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113900 · Cited by 157
Rizvi, F., Everton, E., Smith, A. R., Liu, H., Osota, E., Beattie, M. B., Tam, Y. K., Pardi, N., Weissman, D., & Gouon–Evans, V. (2021) · Nature Communications · doi:10.1038/s41467-021-20903-3 · Cited by 155
Blakney, A. K., Zhu, Y., McKay, P. F., Bouton, C. R., Yeow, J., Tang, J., Hu, K., Samnuan, K., Grigsby, C. L., Shattock, R. J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c00326 · Cited by 155
Effects of Chemically Modified Messenger RNA on Protein Expression
Li, B., Luo, X. L., & Dong, Y. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00090 · Cited by 154
Yang, J., Wu, S., Hou, L., Zhu, D., Yin, S., Yang, G., & Wang, Y. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.06.013 · Cited by 154
Granot-Matok, Y., & Peer, D. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.015 · Cited by 160
SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis
Velikova, T. V., & Georgiev, T. (2021) · Rheumatology International · doi:10.1007/s00296-021-04792-9 · Cited by 153
Metadata
- Authors
- Sahin, U., Karikó, K., & Türeci, Ö.
- Affiliations
- BioNTech (Germany) (DE)
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Karikó, Katalin
- Türeci, Özlem
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-09-19
- Volume
- 13
- Issue
- 10
- Pages
- 759-780
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1963706689
- Cited by
- 2,474
- References
- 256
- Citations by year
- 2026: 296 · 2025: 348 · 2024: 341 · 2023: 312 · 2022: 339 · 2021: 289 · 2020: 143 · 2019: 115 · 2018: 98 · 2017: 81 · 2016: 77 · 2015: 32 · 2014: 2
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- in vitro transcribed mRNA, mRNA therapeutics, mRNA vaccines, cancer immunotherapy, protein replacement therapy, genome editing, designer nucleases, immunogenicity, biopharmaceutical development
- MeSH terms
- Animals, Humans, Immunotherapy, Proteins, RNA, Messenger, Drug Design, Drug Delivery Systems, Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
